Office of Research
Clinical Trials

Investigating NBTXR3 and Radiation for Head and Neck Cancer

This study is testing a treatment called NBTXR3 to see how well it works when combined with radiation therapy, compared to just using radiation therapy with or without a drug called cetuximab. The research is focused on elderly patients who have advanced head and neck squamous cell cancer but cannot undergo platinum-based chemotherapy. Participants will be randomly assigned to two groups; one will receive NBTXR3 with radiation therapy, and the other will receive radiation therapy alone or with cetuximab as chosen by their doctor. The goal is to track how long patients live without their cancer getting worse and overall survival, among other measures. The treatment happens over 7 weeks, with a series of follow-up visits planned afterward.

This study may be appropriate for those with: Metastatic Cancer

Amivantamab Versus Cetuximab in cSCC

This study is testing a new treatment approach for people with cutaneous squamous cell skin cancer that has come back or spread and who have weakened immune systems. Participants are placed into one of two groups. One group gets amivantamab given under the skin together with hyaluronidase to help the drug stay in the body longer. The other group gets cetuximab given into a vein. Treatment is given in 28-day cycles for up to about 24 cycles unless the cancer gets worse or side effects are too severe. Doctors will check safety, how well the cancer responds, and how long people live without cancer growth. Blood tests and scans will be done throughout treatment, and some patients will be followed afterward for years. The study also collects samples for future research.

This study may be appropriate for those with: Metastatic Cancer

Contact UCCC CTO for Study Activation

Specific study details/protocols can be provided upon request

HNSCC Longitudinal Multiomic Study

This is a non‑interventional, forward‑looking study that will collect blood and tumor tissue from adults with metastatic or unresectable recurrent head and neck squamous cell carcinoma who are starting first‑line anti‑PD‑1 or anti‑PD‑L1 therapy as part of usual care. Samples will be tested using next‑generation sequencing (NGS), circulating tumor DNA (ctDNA) assays, RNA and immune profiling, and other multiomic techniques. Collections occur at baseline and at multiple time points during treatment and follow up. The goal is to find biomarkers that help predict who will benefit from treatment, understand how cancers become resistant, and link biomarker changes to real‑world outcomes like survival and time to next treatment. Participants are followed for up to five years; no experimental treatments are provided as part of the study.

This study may be appropriate for those with: Metastatic Cancer

Amivantamab added to carboplatin and pembrolizumab vs standard platinum regimens in treatment‑naive R/M HNSCC

This study is to see how well a treatment that includes amivantamab, pembrolizumab and carboplatin works compared to a different treatment that includes 5-FU, pembrolizumab and platinum (carboplatin or cisplatin) therapy. 5-FU, pembrolizumab and platinum (carboplatin or cisplatin) are already used together to treat recurrent/metastatic head and neck squamous cell carcinoma.

This study may be appropriate for those with: Metastatic Cancer

Testing a New Combination Therapy for Advanced Lung Cancer

This study is looking at a new treatment combination for people with advanced lung cancer who have stopped responding to typical immune checkpoint inhibitors. The new combination includes the drugs N-803, tislelizumab, and docetaxel vs. just docetaxel alone, to see which is more effective in extending patients' lives. Adults 18 or older with this specific type of cancer could participate if they meet certain health requirements. Key aspects include the ability to follow the study procedures, managing contraception requirements, and having a specific level of health for various bodily functions. Some individuals will not qualify if they have recent treatments that conflict with the new drugs, have severe allergies to study drugs, or other significant health concerns.

This study may be appropriate for those with: Metastatic Cancer

Heart Health Screening During Cancer Care

The study looks at CT scans already done for radiation planning to see if there are signs of heart disease. Adults receiving curative radiation may join. Participation involves surveys and sharing scan findings with doctors. This may help find heart disease earlier.

Study of Rilvegostomig vs. Pembrolizumab with Chemotherapy for Lung Cancer

This study is testing two treatments for people with a specific type of lung cancer called metastatic squamous non-small cell lung cancer (NSCLC). It's for patients whose tumors test positive for a marker called PD-L1. The main goal is to see if a new drug, rilvegostomig, combined with chemotherapy, helps people live longer or stop their cancer from progressing more than the standard treatment, pembrolizumab, combined with chemotherapy. Patients will be randomly placed into either treatment group and both will be blind to which they are receiving to ensure fair results. The study will check how well the treatments work over approximately five years, looking specifically at survival rates and the control over cancer growth and spread. Safety and side effects are also being monitored.

This study may be appropriate for those with: Metastatic Cancer

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

This study aims to determine whether rectal cancer's response to treatment is the same when patients receive chemotherapy alone before limited surgery versus when they receive both chemotherapy and radiation therapy before limited surgery, and if omitting radiation therapy improves quality of life.

This study may be appropriate for those with: Newly Diagnosed Cancer

Comparing Effectiveness of Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

This phase II study evaluates the effectiveness of mosunetuzumab versus rituximab, the standard treatment, in extending survival for patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Both mosunetuzumab and rituximab are monoclonal antibodies targeting the CD20 protein on B cells and certain cancer cells, potentially enhancing the immune system's ability to destroy cancer cells. The trial aims to determine if mosunetuzumab offers a superior survival benefit compared to rituximab for individuals with NLPHL.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Dose Escalation/​Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 alone or with Pembrolizumab

This clinical trial is assessing a new treatment, called TEV-56278, which is being tested alone and in combination with another drug called Pembrolizumab. This trial focuses on individuals who have advanced solid tumors. These types of tumors might be resistant to standard treatments or have not responded well to them. This study, conducted by Teva Branded Pharmaceutical Products, aims to find a safe and effective dosage of TEV-56278. It hopes to determine whether it can effectively inhibit tumor growth when used on its own or together with Pembrolizumab. Participants will be observed for any side effects and to see how well the tumor responds to the treatment. The study duration includes being treated for up to one year and followed for up to another year, totaling a possible two years per participant. The trial is ongoing, offering treatment possibilities for those who meet specific inclusion criteria, including having previously received treatment for their tumor and having a life expectancy of at least 12 weeks.

This study may be appropriate for those with: Metastatic Cancer

Radiation With Cetuximab or Chemotherapy

This phase 3 trial compares two treatments given with high-precision radiation therapy (IMRT) for people with advanced head and neck cancer who cannot take cisplatin. Patients are randomly placed into one of two groups. One group gets weekly cetuximab (a drug that targets the EGFR protein on some cancer cells) together with 35 daily radiation treatments over about 7 weeks. The other group gets weekly carboplatin and paclitaxel chemotherapy together with the same radiation schedule. Patients have scans and blood tests during the study and are followed after treatment at 30 days, then at 4, 6, 12, 18, 24, 30, and 36 months and then yearly. The main goal is to compare progression-free survival between the two groups. Secondary goals include comparing overall survival, side effects, where the cancer returns if it does, and changes in eating and speaking function.

This study may be appropriate for those with: Metastatic Cancer

Beat AML Biomarker Treatment Trial

This study is a master protocol that screens people with acute myeloid leukemia (AML) using rapid lab and genomic testing. Based on the test results, each person is placed into one of several smaller treatment studies that test targeted, investigational therapies or drug combinations. The goal is to complete testing and assign patients to a matched treatment within 7 days, and then follow treatment responses and safety over time. The trial includes groups for newly diagnosed patients, relapsed or refractory patients, and a marker-negative group for those who don't match a specific marker. Some sub-studies focus on older adults or patients who cannot or choose not to get intensive chemotherapy. Follow-up can continue for years to track responses and changes in disease over time.

This study may be appropriate for those with: Newly Diagnosed Cancer

Bladder Preservation Immunoradiation

This Phase II study tests whether combining the immune drug pembrolizumab with radiation therapy can allow people with muscle invasive bladder cancer to keep their bladder after the tumor has already shrunk from pre-surgery chemotherapy. Eligible patients have an excellent clinical response after neoadjuvant chemotherapy and will receive daily photon radiation to the bladder Monday through Friday for up to about 4 weeks while also getting pembrolizumab through an IV every 3 weeks. Before joining, patients have had a TURBT (a bladder tumor biopsy/removal procedure) and staging scans. The study tracks how long patients keep their bladder without cancer returning, whether they later need bladder removal (salvage cystectomy), survival outcomes, side effects, and patient-reported symptoms. Blood, urine, and tissue samples will be stored for future research. After finishing treatment, participants are followed regularly for up to 5 years.

This study may be appropriate for those with: Newly Diagnosed Cancer

AMXT1501 and DFMO With Standard Care

This open-label Phase 1b/2 study tests two oral drugs, AMXT 1501 and DFMO, given together with standard treatments in people with advanced ER+ / HER2- breast cancer or with unresectable or metastatic cutaneous melanoma. AMXT 1501 blocks tumor uptake of polyamines and DFMO lowers polyamine production; together they aim to reduce tumor-supporting molecules and possibly improve responses to standard therapy. In the breast cancer group the combo is given with fulvestrant and capivasertib. In the melanoma group the combo is given with pembrolizumab. The Phase 1b part uses a small dose-escalation plan to find a safe dose for Phase 2. The Phase 2 part will look for signs the treatment controls or shrinks tumors using standard tumor response rules. The study also checks drug levels in blood, changes in tumor tissue and immune genes, and overall safety. About 92 patients may be enrolled across the two groups. Participants will have screening tests, regular clinic visits each treatment cycle (28 days), imaging to measure response, and follow-up visits.

This study may be appropriate for those with: Metastatic Cancer

Study on IOV-4001 for Advanced Melanoma and NSCLC

This study is the first-in-human study of IOV-4001, a genetically modified autologous tumor- infiltrating lymphocytes (TIL) product. IOV-4001 is expected to have antitumor activity through its capacity to directly target and kill tumor cells in a manner that is similar to non-genome-edited TIL, but with the potential for enhanced antitumor activity due to disruption of PDCD1, the gene for programmed cell death protein-1 (PD-1).

This study may be appropriate for those with: Metastatic Cancer

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with metastatic kidney cancer. Patients will receive 1 of the following 4 treatment options: Nivolumab 240 mg IV 1 q 2 weeks, Nivolumab 480 mg IV 1 q 4 weeks, Pembrolizumab 200 mg IV 1 q 3 weeks and Axitinib 5 mg oral Daily BID, OR Avelumab 10 mg/kg IV 1 q 2 weeks and Axitinib 5 mg oral Daily BID. Those in Arm 2 will also undergo a radical or partial nephrectomy. Efficacy will be measured by determining Overall Survival.

This study may be appropriate for those with: Newly Diagnosed Cancer

Higher Dose Radiation Therapy for Advanced Pancreatic Cancer Trial

This study is exploring if giving higher doses of radiation can help people with advanced pancreatic cancer live longer. Participants must have already undergone 4-6 months of chemotherapy and have stable disease without progression. There are two groups in the study. One group will receive standard treatment, which could include continuing chemotherapy, a normal dose of radiation, or observation. The other group will receive higher doses of radiation over a shorter period to see if it prolongs their survival. Patients will have regular follow-ups and will be checked through blood tests, imaging scans, and tissue biopsies. They are monitored over a period that includes every three-month checkups for two years and then yearly for another three years. This study aims to not only see if survival improves but examine side effects, quality of life, and any changes in disease progression.

This study may be appropriate for those with: Metastatic Cancer

Testing Abemaciclib with 5-Fluorouracil for Metastatic Colorectal Cancer

This clinical trial is investigating how well two drugs, Abemaciclib and 5-Fluorouracil (5-FU), work together in treating people with colorectal cancer that has spread to other parts of the body and hasn't responded to other treatments. The study aims to discover the safest dose of the drug combination that patients can handle without severe side effects. Participants will take Abemaciclib by mouth twice daily, and receive 5-FU through a vein on specific days during each 28-day cycle. Throughout the study, various samples will be collected to track the effectiveness and side effects of the treatment. After finishing the treatment cycles, participants will be monitored every three months for follow-up. Researchers hope this combination will provide a new option for those with this difficult-to-treat cancer type.

This study may be appropriate for those with: Metastatic Cancer

Inotuzumab With Chemotherapy for Young Adults with Newly Diagnosed B-Cell ALL

This trial tests whether adding the antibody drug inotuzumab ozogamicin to a pediatric-style chemotherapy plan helps young adults (about ages 18-39) with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL). All patients first get a standard induction course of chemo. Those who respond are randomly assigned to either continue the standard multi-course chemotherapy plan or get the same chemotherapy plus inotuzumab given on days 1, 8, and 15 of a 28-day cycle (up to two cycles). The main goals are to confirm the added drug is tolerable and to see if it improves the time patients stay free of relapse or death (event-free survival). The study also looks at overall survival, disease-free survival, how much disease is left after treatment, genetic markers, drug side effects, drug levels, and how well patients take their oral medicines. Treatment can continue for months to years depending on the course, and patients are followed closely for many years after finishing treatment.

This study may be appropriate for those with: Newly Diagnosed Cancer

Testing New Treatment for Residual Cancer in B-cell Lymphoma Patients

This study is testing if a new experimental treatment named cemacabtagene ansegedleucel (or cema-cel for short) can help adults with large B-cell lymphoma, a type of blood cancer. Patients who have already finished one round of regular treatment and are still showing signs of leftover cancer according to a special test are being looked at. The study compares cema-cel treatment versus just watching the patients to see which helps more in preventing cancer events and eliminating leftover cancer cells. Participants must have completed standard initial therapy, be over 18, and meet certain health criteria. Those with recent other cancers or serious current infections, among other things, cannot join. The study will check for various outcomes over several months to see how well cema-cel works and note any side effects.

This study may be appropriate for those with: Newly Diagnosed Cancer

Trastuzumab Deruxtecan Endometrial Study

This global Phase 3 study is testing whether a targeted treatment called trastuzumab deruxtecan (T-DXd) given after surgery can help people with HER2-positive endometrial cancer live longer without the cancer returning. Participants who have newly diagnosed Stage IIC or Stage III endometrial cancer and whose tumors show HER2 will be randomly placed into one of two groups: T-DXd or standard chemotherapy (with or without radiotherapy as decided by the treating doctor). The main goal is to compare the time until cancer returns or the person dies. Doctors will also track overall survival and side effects. T-DXd is a drug that seeks out cancer cells carrying the HER2 protein and delivers a chemotherapy payload directly to them. The study is open-label, which means doctors and patients will know which treatment is given. People will be followed for several years to monitor benefit and safety, including watching for lung inflammation and heart problems, which can be serious with these kinds of treatments.

This study may be appropriate for those with: Newly Diagnosed Cancer

Phase I/​ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Head and Neck Cancer

This study tests a short course of radiation (either standard X-ray photon radiation or proton radiation) given before surgery together with the immunotherapy drug pembrolizumab for people with recurrent head and neck squamous cell carcinoma. Phase I will enroll small groups to find a safe radiation dose and make sure combining the treatments before surgery is tolerable. Phase II will randomly assign patients to receive either proton or photon radiation plus pembrolizumab before salvage surgery and compare the rate of major pathologic response (very low remaining tumor on the removed tissue) to historical results. About 40 patients will be screened and randomized. Key goals are safety, whether the combination increases major pathologic response, and longer-term outcomes like disease-free and overall survival. The study includes tissue and immune testing to learn how the treatments affect the tumor and microenvironment.

This study may be appropriate for those with: Recurrent Cancer

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA SCC of the Head and Neck

This is a phase II study evaluating the disease-free survival (DFS) of patients with stage III-IV squamous cell carcinoma of the head and neck (SCCHN) and disruptive p53 mutations after primary surgical resection followed by postoperative radiotherapy (PORT) alone or PORT with concurrent cisplatin. Participants in Arm A will undergo IMRT 5 days a week for 6 weeks, and those in Arm B will receive the same RT plus weekly Cisplatin via IV.

This study may be appropriate for those with: Newly Diagnosed Cancer

A Study of DB-1311 in Advanced/​Metastatic Solid Tumors

This Phase 1/2a trial aims to assess the safety and tolerability of DB-1311 in patients with advanced solid tumors through dose-escalation and dose-expansion studies.

This study may be appropriate for those with: Metastatic Cancer

Testing Venetoclax for Relapsed Hairy Cell Leukemia

This study is investigating the effectiveness of the drug venetoclax in patients whose hairy cell leukemia has returned after initial treatment. Venetoclax works by blocking a protein necessary for cancer cell survival, potentially reducing cancer growth. Participants will take venetoclax daily in cycles, and their response will be monitored through medical tests, including blood samples and imaging scans. The study aims to measure the overall response rate, complete remission, and any side effects. Eligible participants are those who have not had prior venetoclax treatment and meet specific health criteria. People with certain conditions or allergies should not participate. The study will follow participants for 30 days after their last medication dose to assess outcomes.

This study may be appropriate for those with: Relapsed / Refractory Cancer

DB 1311 Combination Trial

This is an open-label Phase 2 study testing DB-1311 given with either BNT327 or DB-1305 in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study aims to check safety, side effects, how the body processes the drugs, and early signs of benefit like tumor shrinkage and longer time without disease growth. Eligible participants have one of several cancer types (liver cancer, cervical cancer, melanoma, head and neck cancer, platinum-resistant ovarian cancer, or non-small cell lung cancer) and meet basic health and lab criteria. People who previously received certain similar antibody-drug treatments, have serious uncontrolled illnesses, active brain metastases, autoimmune disease, or unresolved severe side effects are not allowed. Participants will receive study drugs in repeated treatment cycles and be seen regularly for safety checks, scans, and blood tests. The study may follow participants for up to about 6 years to collect long-term safety and outcome data.

This study may be appropriate for those with: Metastatic Cancer

New Treatments for Recurrent Glioblastoma

This clinical trial studies new drug combinations for treating people with recurrent glioblastoma, a type of brain cancer that has returned. The trial is testing whether the combination of two monoclonal antibodies, relatlimab and nivolumab, can be as effective or more effective than the current standard treatment, lomustine. These drugs work by potentially interfering with the ability of tumor cells to grow and spread. Participants will be randomly assigned to receive either the experimental drug combination or the standard chemotherapy drug. They will undergo regular checks, including MRI scans and biopsies, to track their response to treatment. The study will compare survival times and patient health outcomes between the two treatment groups over various periods up to 5 years to understand the effectiveness and safety of these treatments.

This study may be appropriate for those with: Recurrent Cancer

Vorasidenib with Temozolomide Trial

This Phase 3 clinical trial tests whether adding vorasidenib to the usual post‑radiation chemotherapy (temozolomide) helps people with newly diagnosed IDH‑mutant grade 3 astrocytoma. Patients are randomly assigned to one of two groups: both get standard radiation followed by temozolomide tablets, and one group also gets vorasidenib tablets while the other gets a placebo. Treatment cycles are 28 days, with the study drug taken daily and temozolomide given on days 1-5 of each cycle, for up to 12 months if the disease does not get worse and side effects are acceptable. Doctors will check tumor status with regular MRI scans and blood tests. The main goal is to see whether adding vorasidenib delays tumor growth (progression‑free survival). The study also looks at safety, overall survival, tumor response, time to next treatment, seizure control, and quality of life. After finishing study drugs, participants are followed for several years to monitor long‑term outcomes.

This study may be appropriate for those with: Newly Diagnosed Cancer

Early Pelvic Floor Therapy Study

This is a small single group study of 28 women with invasive cervical cancer who will get pelvic external beam radiation as part of their treatment. About four weeks after finishing radiation, participants will begin pelvic floor physical therapy. The study will measure how many women have fecal incontinence three months after radiation using a standard patient survey (EORTC QLQ CX24). A survey score of 1 or higher will count as incontinence. The study will also look at urinary incontinence, sexual symptoms, overall quality of life, how well participants follow recommended dilator use, and changes in pelvic floor muscle function (measured with the Brink scale). Assessments will be done before therapy and at three months after radiation. The goal is to see how common bowel leakage is after pelvic radiation and whether early pelvic floor therapy can be studied further as a supportive care approach.

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study on New Treatment for Recurrent Ovarian Cancer

This study is looking at how effective and safe a new drug called sacituzumab tirumotecan, alone or with another drug called bevacizumab, is compared to the usual treatments for people whose ovarian cancer has come back after responding well to platinum-based chemotherapy. The study hopes to find out if patients can live longer without their cancer getting worse with this new treatment and if it's tolerable and safe. They will measure how patients respond to the treatment and monitor any side effects. The trial is in its third phase and will take place over four years.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Study of Sapanisertib and Serabelisib with Paclitaxel for Endometrial Cancer

This clinical trial aims to test a new treatment combining sapanisertib, serabelisib, and paclitaxel for patients with advanced or recurrent endometrial cancer. This study specifically looks at participants who have undergone previous cancer treatments, such as platinum-based chemotherapy and immune checkpoint inhibitors, without success. The treatment is intended for patients who cannot be helped with surgery or radiation. To join, participants need to show specific genetic alterations related to cancer growth. The trial will measure how well the cancer responds to treatment using these medications and will check for any side effects. It's open to women who are postmenopausal or agree to use contraceptives. Participants will be monitored over several years to assess how their cancer progresses and their overall survival. However, those with other recent cancers or certain medical conditions affecting drug absorption or interaction are not eligible.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Effect of a Virtual Reality Cognitive Training Intervention for Brain Cancer Survivors

You will either be assigned to a group that uses the virtual reality training system or a group that will complete paper word search puzzles. At the start of the study all participants will be asked to complete three short cognitive tests to check your current memory and thinking skills. You will take the same tests again at the end of the study to see if anything has changed or improved. You will receive a schedule based on your start and end dates that explains which days you will need to complete the study-related tasks. You will complete the tasks at home for 4 weeks, 6 days a week. It will start at 15 minutes a day in week one and increase by 5 minutes each week, ending at 30 minutes a day in week four. You will receive either a VR headset and hand controllers for use with VR-CRT (and portable WI-FI hotspot if you do not have WI-FI at home) or a notebook for use with paper word-search puzzles (WSP). The research study will provide the technology to you free of charge, but with a technology sign-out consent to confirm your agreement to return the VR and WI-FI equipment once the study is completed. If you are in the VR group, you will be trained on how to use the equipment and how to connect the VR equipment to WIFI. Off-the-shelf VR equipment (Meta Quest 3/128 GB with WIFI) will be used.

Testing a New Combo Therapy for Relapsed Aggressive B-cell Lymphoma

This trial studies how well a combination of drugs called ViPOR works for patients with a type of aggressive lymphoma that has returned after treatment or not responded to previous treatments. ViPOR combines 5 drugs: venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid. Each has its own function, but together they aim to stop cancer cells from growing by targeting specific proteins and supporting the immune system's ability to attack these cancer cells. This research will see whether this drug mix can help the patient's lymphoma disappear fully and track patients' survival over time. Participants will receive these medicines in cycles every 21 days for up to 6 cycles and might have tests like blood tests and scans along the way. The study checks if this treatment stops the lymphoma from growing and how safe it is.

This study may be appropriate for those with: Relapsed / Refractory Cancer

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

This clinical trial examines the effectiveness and safety of a new drug, UGN-104, for patients with low-grade upper tract urothelial cancer. During the study, UGN-104 is administered directly into the upper urinary tract once a week for six weeks. Patients who show no signs of cancer after these treatments will have follow-up visits and may continue receiving monthly doses as a maintenance treatment plan for up to one year. These maintenance visits help ensure that the cancer does not return. The study involves regular check-ups every three months and lasts up to 15 months. Participants must have been diagnosed with this type of cancer and should not have received certain other treatments or have specific health conditions.

This study may be appropriate for those with: Recurrent Cancer

Cretostimogene in High Risk NMIBC

This Phase 2 study tests a virus based drug called cretostimogene grenadenorepvec given directly into the bladder to treat high risk non muscle invasive bladder cancer. The study has several groups: patients who never had BCG vaccine treatment, those who previously had BCG, and a group that is BCG unresponsive or exposed. Some patients are randomly assigned to different ways of putting the drug into the bladder, and one group will get the drug with the chemotherapy drug gemcitabine either at the same time or one after the other. Treatment starts with a weekly induction for 6 weeks. If needed, a reinduction is given at 3 months. If high grade cancer is gone, maintenance treatments follow: three weekly treatments every 3 months in year 1, then every 6 months in year 2, with an optional extension into year 3. Doctors check disease with urine tests and bladder exams every 3 months for 2 years, then every 6 months for up to 4 years total or until the cancer returns. The study looks at response rates, how long patients stay free of high grade events, and safety.

This study may be appropriate for those with: Metastatic Cancer

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

This study may be appropriate for those with: Newly Diagnosed Cancer

Cemiplimab CDX-1140 Before Surgery

This is a randomized phase 2 study for adults with stage III or IV head and neck squamous cell cancer who are scheduled for surgery. Patients are placed into one of two groups. One group receives cemiplimab (an anti PD‑1 immunotherapy) before surgery. The other group receives one dose of the anti‑CD40 drug CDX‑1140 followed a few days later by cemiplimab before surgery. Surgery is planned about 4 to 5 weeks after treatment. After surgery patients receive standard care as needed and are followed for up to two years. The main goal is to compare how often the removed tumor shows a major pathologic response (very little viable cancer left) between the two groups. The study also checks safety and side effects, looks at tumor and blood markers (including gene expression and circulating tumor DNA), studies immune changes in the tumor, and measures drug levels. Visits include screening tests, treatment infusions, the surgery visit, and follow up visits at about weeks 9–10 and 18, at 6 months, and then every 3–6 months for two years.

This study may be appropriate for those with: Metastatic Cancer

Study on Teclistamab and Talquetamab for Treating Multiple Myeloma

This study is testing two new treatment combinations for people with newly diagnosed multiple myeloma who can't have a stem cell transplant right away. It explores if mixing new drugs, teclistamab and talquetamab, with daratumumab and lenalidomide works better than the usual treatment that includes daratumumab, lenalidomide, and dexamethasone. The main goal is to see how long participants live without their disease getting worse. Researchers will also monitor how many people have no signs of cancer after a year. People who join this study should not have been treated for multiple myeloma before (except for some steroids) and must meet health criteria like not planning pregnancies. It excludes people with recent severe health issues or allergies to the drugs used. The study could last up to nine years for each participant.

This study may be appropriate for those with: Newly Diagnosed Cancer

Blood Test for ctDNA in Guiding Immunotherapy After Bladder Cancer Surgery

This study investigates whether a blood test can detect leftover cancer after bladder surgery and guide further treatment using immunotherapy. It aims to identify patients who might need additional treatment to prevent cancer from coming back. The study uses blood tests to look for circulating tumor DNA (ctDNA), which can indicate cancer presence. Patients testing positive for ctDNA might receive immunotherapy drugs nivolumab and relatlimab, while those who test negative might not get additional treatment immediately. This research hopes to improve survival rates and quality of life for bladder cancer patients by tailoring immunotherapy based on ctDNA results.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study of JZP898 for Advanced/Metastatic Solid Tumors

This clinical research study is focused on understanding how a new drug called JZP898 works in adults who have advanced or metastatic solid tumors. The study is taking place in two parts. In the first part, researchers are exploring how the drug works on its own and when combined with another drug, pembrolizumab. They aim to find a safe dosage and look for any potential side effects. In the second part, they will further explore the effects of the combination of these two drugs on different types of tumors. The researchers want to know if these treatments can shrink the tumors and are safe for people to use over a long time. They will keep track of how the participants react to the treatment and measure things like how long the drug stays in their system and if it has any unwanted effects. People who want to participate must meet certain conditions, like having a specific kind of tumor and being able to care for themselves daily without too much help. This study is supported by Jazz Pharmaceuticals.

This study may be appropriate for those with: Metastatic Cancer

Study on ABBV-383 for Relapsed or Refractory Multiple Myeloma

This study focuses on testing the safety and dose optimization of a new drug, ABBV-383, for adults with relapsed or refractory multiple myeloma, a type of blood cancer. Researchers are trying to find the best way to use this drug by looking at different dose levels. They will monitor participants for adverse effects like cytokine release syndrome, which can cause symptoms like fever and low blood pressure. The study includes three groups, each with different dosing plans. Around 180 participants will be treated with ABBV-383 as an IV infusion every 28 days for about three years. Throughout the study, participants will undergo medical checks and fill out questionnaires to track their health and any side effects.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Monitoring in Breast Cancer- ctDNA

This study follows people with breast cancer over time to see whether tiny amounts of cancer DNA in the blood (called circulating tumor DNA or ctDNA) can show if cancer remains after treatment and predict if it will come back. Participants give blood samples at different times: during pre-surgery treatment, after surgery, during routine follow-up, and up to long-term monitoring. The study includes patients receiving pre-surgery treatment, those who have completed surgery and have no visible disease, and people who have been disease-free for five years but were originally at higher risk. Researchers will use DNA sequencing of the blood to look for signs of minimal residual disease (MRD). The main goal is to compare disease-free survival between people with and without detectable ctDNA. Secondary goals examine distant recurrence, overall survival, how MRD relates to tumor response after surgery, and how long it takes from a first positive ctDNA test to clinical recurrence. The study is observational - it only collects samples and clinical information - and aims to improve early detection of recurrence and help guide future tests and treatments.

Trial of BNT113 and Pembrolizumab for HPV16+ Head and Neck Cancer

This study is for patients who have a type of head and neck cancer that is linked to a virus called Human Papilloma Virus 16 (HPV16). The research is exploring whether a new treatment, using a vaccine called BNT113 together with a medicine called pembrolizumab, works better than just using pembrolizumab alone. Pembrolizumab is already a common treatment for this kind of cancer. The study is being conducted by BioNTech SE and involves patients who haven't been treated with systemic therapy for their cancer before. The first part of the study looks at safety to make sure the new combination doesn't cause serious side effects. The second part of the study compares how long patients live and how well their cancer responds to the different treatments. Those interested in participating need to have certain types of tumors that are both HPV16 positive and express a protein called PD-L1.

This study may be appropriate for those with: Metastatic Cancer

Study of ZE50-0134 for Chronic Lymphocytic Leukemia and Lymphomas

This clinical trial is mainly for adults who have a type of blood cancer known as Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), as well as some other related low-grade lymphomas. The study aims to test a new treatment called ZE50-0134. It's designed to see how safe the medicine is, how it moves through the body, and how well it works against these illnesses. In the first part of the study, doctors will try different doses to find the highest amount patients can handle safely. In the second part, they will explore how effective this dose is and confirm safety with a focus on long-term usage. Patients will participate in multiple cycles of treatment, each cycle lasting four weeks, up to a total of 24 cycles, but detailed visits depend on patient grouping and specific needs. This trial is open label, meaning patients will know they are receiving ZE50-0134. Participants must be at least 18 years old and have already tried some other treatments unsuccessfully. They shouldn't have certain health issues like active infection, severe heart problems, or recent surgery. Pregnancy testing is required for women of childbearing potential before starting the drug.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Safety and Effectiveness of PYX-201 in Solid Tumors

This study is testing a new drug called PYX-201 in adults with advanced solid tumors that have not responded to usual treatments or for whom there are no suitable treatment options. The goal is to find out what dose of the drug is safe and can be tolerated well. Researchers will monitor participants to see how their bodies react to the drug, including any side effects and how the drug moves through their system. Participants must be adults with certain cancers, such as breast, lung, or ovarian cancer, who meet health criteria like having normal kidney and liver function. The study aims to explore both the safety and preliminary effectiveness of PYX-201 over approximately 3 years. It is open-label, meaning all participants receive the drug, and no placebo is involved. Measurements will focus on potential toxicities and adverse events as well as biological markers from blood samples. Participants must not have severe infections or other active cancers. The research hopes to pave the way for further clinical development if results are promising.

This study may be appropriate for those with: Recurrent Cancer

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations. Participants will choose to undergo surgery to remove the fallopian tubes only and plan to have the ovaries removed in the future (BLS group) or remove the fallopian tubes and ovaries at the same time (BSO group).

This study may be appropriate for those with: Newly Diagnosed Cancer

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving CA-4948 in combination with gemcitabine and nab-paclitaxel may shrink or stabilize metastatic or unresectable pancreatic ductal adenocarcinoma.

This study may be appropriate for those with: Metastatic Cancer

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

The main purpose of this study is to measure the safety and effectiveness with ivonescimab/SMT112 in combination with chemotherapy drugs, i.e., FOLFOX (Oxaliplatin, Leucovorin and Fluorouracil) in the first-line treatment of metastatic colorectal cancer (mCRC) compared to bevacizumab in combination with chemotherapy drugs, i.e., FOLFOX (Oxaliplatin, Leucovorin and 5-Fluorouracil). Ivonescimab/SMT112 is considered investigational and has not been approved by the U.S. Food & Drug Administration/local Regulatory Authority for treatment or sale. Bevacizumab is a different approved drug sold under the brand name Avastin. FOLFOX is a standard chemotherapy regimen made up of the drugs folinic acid (leucovorin, FOL), fluorouracil (5-FU, F), and oxaliplatin (Eloxatin, OX).

This study may be appropriate for those with: Metastatic Cancer